background:
Rho GTPase activating protein 29 is a GTPase activator for the Rho-type GTPases. It converts them to an inactive GDP-bound state. It has strong activity toward RHOA and weaker activity toward RAC1 and CDC42. It also may act as a specific effector of RAP2A to regulate Rho. There are two named isoforms produced by alternative splicing.
Rho GTPase activating protein 29 is widely expressed; highly expressed in skeletal muscle and heart; expressed at intermediate level in placenta, liver and pancreas; weakly expressed in brain, lung and kidney.
Function:
GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Has strong activity toward RHOA, and weaker activity toward RAC1 and CDC42. May act as a specific effector of RAP2A to regulate Rho. In concert with RASIP1, suppresses RhoA signaling and dampens ROCK and MYH9 activities in endothelial cells and plays an essential role in blood vessel tubulogenesis.
Subunit:
Interacts with PTPN13/PTPL1. Interacts with RAP2A via its coiled coil domain. Interacts with RASIP1 (By similarity).
Tissue Specificity:
Widely expressed. Highly expressed in skeletal muscle and heart. Expressed at intermediate level in placenta, liver and pancreas. Weakly expressed in brain, lung and kidney.
Similarity:
Contains 1 phorbol-ester/DAG-type zinc finger.
Contains 1 Rho-GAP domain.
Database links:
UniProtKB/Swiss-Prot: Q52LW3.2
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
|
|
